IDH1 and central nervous system cancer: Notably, while our longest survivor still on protocol therapy (S021) has molecularly confirmed DMG, another long-term survivor (S008) has a high-grade glioma with an IDH1 mutation that is associated with improved survival, as are mutations in BRAF as seen in S045.